Accessibility Menu
Opus Genetics logo

Opus Genetics(NASDAQ) OCUP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-49%
5 Year-26%
1 Year+155%
1 Month-17%
N/A
Opus Genetics last closing stock price
MetricPriceDate
Last closeUSD 3.082026-07-24
Opus Genetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.81%USD 3.272026-07-17
1 month-16.98%USD 3.712026-06-24
3 month-41.11%USD 5.232026-04-24
Year to date+53.23%USD 2.012025-12-31
1 year+154.55%USD 1.212025-07-24
3 year-22.61%USD 3.982023-07-25
5 year-26.32%USD 4.182021-07-23
Since inception-48.67%USD 6.002020-11-06

Opus Genetics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.37M

Net Income (TTM)

-$106.93M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 11, 2024

OCUP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opus Genetics

Opus Genetics creates treatments to help people with rare eye diseases see better. These therapies aim to fix the genetic causes of blindness that often start in childhood. The company also makes eye drops for common vision issues like pupil dilation.

What's in the Pipeline?

  • Gene Therapy Programs: One-time treatments designed to fix the underlying genetic causes of severe retinal disorders like LCA5 and BEST1.
  • RYZUMVI: FDA-approved eye drops used to reverse pupil dilation after eye exams; marketed through a partnership with Viatris.
  • Presbyopia Solutions: Investigative therapies for age-related near vision loss, which involves a progressive loss of ability to focus on close objects.
  • Retinal Disease Drugs: Oral medications like APX3330 targeting diabetic retinopathy, a condition where high blood sugar damages the back of the eye.

Big Moves and Partnerships

  • Acquired Private Opus in October 2024 to focus on gene therapies for inherited retinal diseases (IRDs).
  • Signed a license agreement with Viatris in November 2022 to develop and commercialize phentolamine ophthalmic solution products.
  • Purchased assets from Iveric in December 2022 to gain control over the BEST1 and RHO genetic programs.
  • Launched a clinical trial for the MERTK program in Abu Dhabi in January 2026 with Cleveland Clinic Abu Dhabi.

Why Opus Stands Out

Opus uses a portfolio approach to target rare eye diseases where no other approved treatments exist. The company uses specialized viruses to deliver healthy genes directly into the eye through subretinal injections.

The Money Trail

  • Revenue was $3.9 million in Q4 2025, down 10.2% from $4.3 million in Q4 2024.
  • Gross profit reached $3.9 million in Q4 2025, improving from a $3.5 million loss the previous year.
  • Net income was negative $16.5 million in Q4 2025, an improvement from a $35.1 million loss in Q4 2024.
  • Free cash flow was negative $9.8 million in Q4 2025, worsening by 32.2% year-over-year.

Bottom Line

Opus has evolved from a general eye-care firm into a specialized developer of gene therapies for rare blindness. Its mix of approved products and clinical-stage treatments helps it address both common and rare vision disorders.

AI Generated • May 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

George Magrath, III, MD

Website

opusgtx.com

Headquarters

Farmington Hills, MI 48335, US

OCUP Financials

Key Financial Metrics (TTM)

Gross Margin

49.64%

Operating Margin

-359.13%

Net Income Margin

-892.36%

Return on Equity

6068.79%

Return on Capital

-251.49%

Return on Assets

-160.11%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$4.37M

Operating Income

-$43.03M

EBITDA

-$27.16M

Operating Cash Flow

-$38.99M

Capital Expenditure

$0.00

Free Cash Flow

-$38.99M

Cash & ST Invst.

$59.96M

Total Debt

$0.00

Opus Genetics Performance Analysis

Opus Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 39,850,0006665.7%
20232023-12-31USD 19,049,000-52.2%
20242024-12-31USD 10,992,000-42.3%
20252025-12-31USD 14,196,00029.1%
Opus Genetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Opus Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.87N/A
20232023-12-31USD -0.46N/A
20242024-12-31USD -2.15365.6%
20252025-12-31USD -0.80-63.0%
Opus Genetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3050.0%
Q32025-09-30-108.3%
Q42025-12-3124.0%
Q12026-03-31-294.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

14

N/A

Net Income

-$65.54M

-699.8%

EBITDA

$13.00K

+0.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$59.96M

+43.5%

Total Debt

$0.00

N/A

Accounts Receivable

$2.72M

-42.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.60%

N/A

Return on Invested Capital

-74.91%

N/A

Free Cash Flow

-$12.73M

-41.5%

Operating Cash Flow

-$12.73M

-41.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRCEGrace Therapeutics, Inc.
$2.30-1.29%
MRNSMarinus Pharmaceuticals, Inc.
$0.55+0.00%
ANGNAngion Biomedica Corp.
$1.00+0.00%
ALLKAllakos Inc.
$0.33+0.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About OCUP

What is the current price of Opus Genetics?

Opus Genetics is trading at N/A per share.

What is the 52-week range for Opus Genetics?

Over the past 52 weeks, Opus Genetics has traded between N/A and N/A.

How much debt does Opus Genetics have?

As of the most recent reporting period, Opus Genetics reported total debt of $25.93M.

How much cash does Opus Genetics have on hand?

Opus Genetics reported $59.96M in cash and cash equivalents in its most recent financial results.

What is Opus Genetics’s dividend yield?

Opus Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services